Novel Second-Generation Di-2-Pyridylketone Thiosemicarbazones Show Synergism with Standard Chemotherapeutics and Demonstrate Potent Activity against Lung Cancer Xenografts after Oral and Intravenous Administration in Vivo
摘要:
We developed a series of second-generation di-2-pyridyl ketone thiosemicarbazone (DpT) and 2-benzoylpyridine thiosemicarbazone (BpT) ligands to improve the efficacy safety profile of these potential antitumor agents. Two novel DpT analogues, Dp4e4mT and DpC, exhibited pronounced and selective activity against human lung cancer xenografts in vivo via the intravenous and oral routes. Importantly, these analogues did not induce the cardiotoxicity observed at high nonoptimal doses of the first-generation DpT analogue, Dp44mT. The Cu(II) complexes of these ligands exhibited potent antiproliferative activity having redox potentials in a range accessible to biological reductants. The activity of the copper complexes of Dp4e4mT and DpC against lung cancer cells was synergistic in combination with gemcitabine or cisplatin. It was demonstrated by EPR spectroscopy that dimeric copper compounds of the type [CuLCl](2), identified crystallographically, dissociate in solution to give monomeric 1:1 Cu:ligand complexes. These monomers represent the biologically active form of the complex.
二-2-吡啶基缩氨基硫脲 (DpT) 类似物表现出针对人类肿瘤的有效且选择性的抗增殖活性。目前的研究报告了 Fe( III )、Co( III )、Ni( II )、Cu( II )、Zn( II )、Ga( III ) 和 Pd( II ) 配合物的合成及其化学和生物学表征有前景的第二代 DpT 类似物,二-2-吡啶基酮-4-乙基-4-甲基-3-缩氨基硫脲 (Dp4e4mT)。这些研究表明,与 Cu( II )、Zn( II ) 和 Ga( III ) 的复合物相比, Dp4e4mT Co( III )、Ni( II ) 和 Pd( II ) 复合物在抗增殖功效方面表现出明显的生物活性。癌细胞和涉及氧合肌红蛋白 (oxy-Mb) 和氧合血红蛋白 (oxy-Hb) 氧化的有害脱靶效应。在抗增殖活性方面,Zn( II ) 和 Ga( III ) Dp4e4mT 复合物表现出与 Cu( II )
[EN] THIOSEMICARBAZONE COMPOUNDS AND USE IN THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS DE THIOSEMICARBAZONE ET UTILISATION DANS LE TRAITEMENT DU CANCER
申请人:RICHARDSON DES R
公开号:WO2012079128A1
公开(公告)日:2012-06-21
The present invention relates to dipyridyl thiosemicarbazone compounds of formula (I): wherein R1 is cyclohexyl or ethyl; as well as pharmaceutical compositions containing those compounds, and the use of those compounds and compositions in the treatment of cancer.